Inanovate is a pioneering company in the field of life sciences, specializing in advanced diagnostic solutions for breast cancer detection. Founded in 2007, the company operates from Research Triangle Park, North Carolina, and has built a robust team with over 50 years of combined expertise in life science technology development. Inanovate's core product, the Bio ID platform, integrates multiple patented breast cancer-specific biomarkers to achieve a sensitivity of 83% and a specificity of 70% in identifying breast cancer. This means that over 8 out of every 10 cases of cancer are correctly identified, potentially saving tens of thousands of lives annually and improving the quality of life for millions more. The company collaborates with leading clinical and industrial organizations, including Sanford Health, to validate and expand its diagnostic capabilities through extensive clinical trials. Inanovate's business model focuses on the commercialization of its diagnostic tests, targeting healthcare providers and clinical laboratories as its primary clients. Revenue is generated through the sale of diagnostic kits and services, as well as potential licensing agreements for its patented technologies. The company aims to make a significant impact on clinical practice by providing reliable and accurate diagnostic tools that enhance early detection and treatment of breast cancer.

Keywords: breast cancer detection, diagnostic solutions, Bio ID platform, biomarkers, clinical trials, life sciences, healthcare providers, commercialization, patented technologies, early detection.